Cargando…
Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives
Each year, almost 4.1 million people are diagnosed with gastrointestinal (GI) cancers. Due to late detection of this disease, the mortality is high, causing approximately 3 million cancer-related deaths annually, worldwide. Although the incidence and survival differs according to organ site, earlier...
Autores principales: | Vedeld, Hege Marie, Goel, Ajay, Lind, Guro E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286571/ https://www.ncbi.nlm.nih.gov/pubmed/29253542 http://dx.doi.org/10.1016/j.semcancer.2017.12.004 |
Ejemplares similares
-
The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer
por: Vedeld, Hege Marie, et al.
Publicado: (2014) -
Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis – The promise of DNA methylation and molecular biomarkers
por: Vedeld, Hege Marie, et al.
Publicado: (2020) -
Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer
por: Vedeld, Hege Marie, et al.
Publicado: (2018) -
The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers
por: Marie Vedeld, Hege, et al.
Publicado: (2015) -
PoDCall: positive droplet calling and normalization of droplet digital PCR DNA methylation data
por: Jeanmougin, Marine, et al.
Publicado: (2022)